BibTex RIS Kaynak Göster

Süperovulasyon Protokolünde Kullanılan GnRH Agonistinin Oosit Olgunluğu ve Çapına Etkileri

Yıl 2008, Cilt: 39 Sayı: 2, 41 - 48, 20.07.2014

Murat Başar Mehmet Türker Tülay İrez Oktay Arda

Anahtar Kelimeler

FSH GnRHa hCG in vitro fertilizasyon oosit çapı süperovulasyon

Kaynakça

  • 1. Guillemin R, Amoss M, Blackwell R, et al. Polypeptides antagonists of the hypothalamic luteinizing hormone releasing factor. Gynecol Invest 1971; 2: 2-12.
  • 2. Schally AV, Nair RM, Redding TW, Arimura A. Isolation of the luteinizing hormone and follicle-stimulating hormone-releasing hormone from porcine hypothalami. J Biol Chem 1971; 246: 7230-7236.
  • 3. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001; 358: 1793- 1803.
  • 4. Gründker C, Schulz K, Günthert AR, Emons G. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 2000; 85: 3815-3820.
  • 5. Fleming R, Adam AH, Barlow DH, et al. A new systematic treatment for infertile women with abnormal hormone profiles. Br J Obstet Gynaecol 1982; 89: 80- 3.
  • 6. Porter RN, Smith W, Craft IL, et al. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 1984; 2: 1284-1285.
  • 7. Fleming R, Conaghan C, Coutts JR. The uses of LH-releasing hormone and analogs in infertility. Ir J Med Sci 1986; 155(12 Suppl): 22-29.
  • 8. Shaw RW, Ndukwe G, Imoedemhe DA, et al. Twin pregnancy after pituitary desensitisation with LHRH agonist and pure FSH. Lancet 1985; 2: 506-507.
  • 9. Wildt L, Diedrich K, van der Ven H, et al. Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins. Hum Reprod 1986; 1: 15-19.
  • 10. Smitz J, Devroey P, Camus M, et al. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum Reprod 1988; 3: 585-590.
  • 11. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 2003; 14: 236-242.
  • 12. Fauser BC, Devroey P, Yen SS, et al. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum Reprod 1999; 14: 2681-2686.
  • 13. Oehninger S, Hodgen GD. Induction of ovulation for assisted reproduction programmes. Baillieres Clin Obstet Gynaecol 1990; 4: 541-573.
  • 14. Trounson A, Mohr L. Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature 1983; 305: 707-709.
  • 15. Zeilmaker GH, Alberda AT, van Gent I, et al. Two pregnancies following transfer of intact frozen-thawed embryos. Fertil Steril 1984; 42: 293-296.
  • 16. Wong WY, Richards JS. Induction of prostaglandin H synthase in rat preovulatory follicles by gonadotropinreleasing hormone. Endocrinology 1992; 130: 3512- 3521.
  • 17. Yoshimura Y, Nakamura Y, Ando M, et al. Protein kinase C mediates gonadotropin-releasing hormone agonist-induced meiotic maturation of follicle-enclosed rabbit oocytes. Biol Reprod 1992; 47: 118-125.
  • 18. Yoshimura Y, Nakamura Y, Oda T, et al. Induction of meiotic maturation of follicle-enclosed oocytes of rabbits by a transient increase followed by an abrupt decrease in cyclic AMP concentration. J Reprod Fertil 1992; 95: 803-812.
  • 19. Lonergan P, Monaghan P, Rizos D, et al. Effect of follicle size on bovine oocyte quality and developmental competence following maturation, fertilization, and culture in vitro. Mol Reprod Dev 1994; 37: 48-53.
  • 20. Pavlok A, Lucas-Hahn A, Niemann H. Fertilization and developmental competence of bovine oocytes derived from different categories of antral follicles. Mol Reprod Dev 1992; 31: 63-67.
  • 21. Carolan C, Lonergan P, Monget P, et al. Effect of follicle size and quality on the ability of follicular fluid to support cytoplasmic maturation of bovine oocytes. Mol Reprod Dev 1996; 43: 477-483.
  • 22. Hazeleger NL, Hill DJ, Stubbing RB, Walton JS. Relationship of morphology and follicular fluid environment of bovine oocytes to their developmental potential in vitro. Theriogenology 1995; 43: 509-522.
  • 23. Suzuki H, Shibata H, Takita T, et al. Steroid contents and cortical steroidogenic enzymes in non-hyperfunctioning adrenal adenoma. Endocr J 1994; 41: 267-274.
  • 24. Krisher RL. The effect of oocyte quality on development. J Anim Sci 2004; 82: E14-23.

Yıl 2008, Cilt: 39 Sayı: 2, 41 - 48, 20.07.2014

Murat Başar Mehmet Türker Tülay İrez Oktay Arda

Kaynakça

  • 1. Guillemin R, Amoss M, Blackwell R, et al. Polypeptides antagonists of the hypothalamic luteinizing hormone releasing factor. Gynecol Invest 1971; 2: 2-12.
  • 2. Schally AV, Nair RM, Redding TW, Arimura A. Isolation of the luteinizing hormone and follicle-stimulating hormone-releasing hormone from porcine hypothalami. J Biol Chem 1971; 246: 7230-7236.
  • 3. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001; 358: 1793- 1803.
  • 4. Gründker C, Schulz K, Günthert AR, Emons G. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 2000; 85: 3815-3820.
  • 5. Fleming R, Adam AH, Barlow DH, et al. A new systematic treatment for infertile women with abnormal hormone profiles. Br J Obstet Gynaecol 1982; 89: 80- 3.
  • 6. Porter RN, Smith W, Craft IL, et al. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 1984; 2: 1284-1285.
  • 7. Fleming R, Conaghan C, Coutts JR. The uses of LH-releasing hormone and analogs in infertility. Ir J Med Sci 1986; 155(12 Suppl): 22-29.
  • 8. Shaw RW, Ndukwe G, Imoedemhe DA, et al. Twin pregnancy after pituitary desensitisation with LHRH agonist and pure FSH. Lancet 1985; 2: 506-507.
  • 9. Wildt L, Diedrich K, van der Ven H, et al. Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins. Hum Reprod 1986; 1: 15-19.
  • 10. Smitz J, Devroey P, Camus M, et al. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum Reprod 1988; 3: 585-590.
  • 11. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 2003; 14: 236-242.
  • 12. Fauser BC, Devroey P, Yen SS, et al. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum Reprod 1999; 14: 2681-2686.
  • 13. Oehninger S, Hodgen GD. Induction of ovulation for assisted reproduction programmes. Baillieres Clin Obstet Gynaecol 1990; 4: 541-573.
  • 14. Trounson A, Mohr L. Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature 1983; 305: 707-709.
  • 15. Zeilmaker GH, Alberda AT, van Gent I, et al. Two pregnancies following transfer of intact frozen-thawed embryos. Fertil Steril 1984; 42: 293-296.
  • 16. Wong WY, Richards JS. Induction of prostaglandin H synthase in rat preovulatory follicles by gonadotropinreleasing hormone. Endocrinology 1992; 130: 3512- 3521.
  • 17. Yoshimura Y, Nakamura Y, Ando M, et al. Protein kinase C mediates gonadotropin-releasing hormone agonist-induced meiotic maturation of follicle-enclosed rabbit oocytes. Biol Reprod 1992; 47: 118-125.
  • 18. Yoshimura Y, Nakamura Y, Oda T, et al. Induction of meiotic maturation of follicle-enclosed oocytes of rabbits by a transient increase followed by an abrupt decrease in cyclic AMP concentration. J Reprod Fertil 1992; 95: 803-812.
  • 19. Lonergan P, Monaghan P, Rizos D, et al. Effect of follicle size on bovine oocyte quality and developmental competence following maturation, fertilization, and culture in vitro. Mol Reprod Dev 1994; 37: 48-53.
  • 20. Pavlok A, Lucas-Hahn A, Niemann H. Fertilization and developmental competence of bovine oocytes derived from different categories of antral follicles. Mol Reprod Dev 1992; 31: 63-67.
  • 21. Carolan C, Lonergan P, Monget P, et al. Effect of follicle size and quality on the ability of follicular fluid to support cytoplasmic maturation of bovine oocytes. Mol Reprod Dev 1996; 43: 477-483.
  • 22. Hazeleger NL, Hill DJ, Stubbing RB, Walton JS. Relationship of morphology and follicular fluid environment of bovine oocytes to their developmental potential in vitro. Theriogenology 1995; 43: 509-522.
  • 23. Suzuki H, Shibata H, Takita T, et al. Steroid contents and cortical steroidogenic enzymes in non-hyperfunctioning adrenal adenoma. Endocr J 1994; 41: 267-274.
  • 24. Krisher RL. The effect of oocyte quality on development. J Anim Sci 2004; 82: E14-23.
Toplam 24 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Araştırmalar
Yazarlar

Murat Başar Bu kişi benim

Mehmet Türker Bu kişi benim

Tülay İrez Bu kişi benim

Oktay Arda Bu kişi benim

Yayımlanma Tarihi 20 Temmuz 2014
Yayımlandığı Sayı Yıl 2008 Cilt: 39 Sayı: 2

Kaynak Göster

APA Başar, M., Türker, M., İrez, T., Arda, O. (2014). Süperovulasyon Protokolünde Kullanılan GnRH Agonistinin Oosit Olgunluğu ve Çapına Etkileri. Cerrahpaşa Tıp Dergisi, 39(2), 41-48.
AMA Başar M, Türker M, İrez T, Arda O. Süperovulasyon Protokolünde Kullanılan GnRH Agonistinin Oosit Olgunluğu ve Çapına Etkileri. Cerrahpaşa Tıp Dergisi. Temmuz 2014;39(2):41-48.
Chicago Başar, Murat, Mehmet Türker, Tülay İrez, ve Oktay Arda. “Süperovulasyon Protokolünde Kullanılan GnRH Agonistinin Oosit Olgunluğu Ve Çapına Etkileri”. Cerrahpaşa Tıp Dergisi 39, sy. 2 (Temmuz 2014): 41-48.
EndNote Başar M, Türker M, İrez T, Arda O (01 Temmuz 2014) Süperovulasyon Protokolünde Kullanılan GnRH Agonistinin Oosit Olgunluğu ve Çapına Etkileri. Cerrahpaşa Tıp Dergisi 39 2 41–48.
IEEE M. Başar, M. Türker, T. İrez, ve O. Arda, “Süperovulasyon Protokolünde Kullanılan GnRH Agonistinin Oosit Olgunluğu ve Çapına Etkileri”, Cerrahpaşa Tıp Dergisi, c. 39, sy. 2, ss. 41–48, 2014.
ISNAD Başar, Murat vd. “Süperovulasyon Protokolünde Kullanılan GnRH Agonistinin Oosit Olgunluğu Ve Çapına Etkileri”. Cerrahpaşa Tıp Dergisi 39/2 (Temmuz 2014), 41-48.
JAMA Başar M, Türker M, İrez T, Arda O. Süperovulasyon Protokolünde Kullanılan GnRH Agonistinin Oosit Olgunluğu ve Çapına Etkileri. Cerrahpaşa Tıp Dergisi. 2014;39:41–48.
MLA Başar, Murat vd. “Süperovulasyon Protokolünde Kullanılan GnRH Agonistinin Oosit Olgunluğu Ve Çapına Etkileri”. Cerrahpaşa Tıp Dergisi, c. 39, sy. 2, 2014, ss. 41-48.
Vancouver Başar M, Türker M, İrez T, Arda O. Süperovulasyon Protokolünde Kullanılan GnRH Agonistinin Oosit Olgunluğu ve Çapına Etkileri. Cerrahpaşa Tıp Dergisi. 2014;39(2):41-8.